Form 4: Immunome CMO Granted 242,000 Stock Options

Immunome Inc.'s Chief Medical Officer, Robert Lechleider, was granted 242,000 employee stock options with an exercise price of $10.60, vesting over time.

Summary

• Robert Lechleider, Chief Medical Officer of Immunome Inc. (IMNM), was granted 242,000 employee stock options.
• The options have an exercise price of $10.60 per share.
• The grant date for these options was July 29, 2025.
• The options expire on July 28, 2035.
• Vesting schedule: 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive like the Chief Medical Officer is a standard practice for aligning management incentives with shareholder interests and retaining talent. It reflects ongoing operations and compensation strategy rather than a specific positive or negative operational outcome.

Positives

• Granting stock options to a Chief Medical Officer aligns their incentives with long-term shareholder value.
• The significant number of options (242,000) indicates a substantial commitment to the executive's role and future performance.
• A long expiration date (July 28, 2035) provides ample time for the options to become in-the-money, reflecting confidence in future growth.

Negatives

• The exercise price of $10.60 means the stock must trade above this price for the options to have intrinsic value, representing a potential dilution if exercised when the stock price is higher.
• The vesting schedule means the full benefit of the options is not immediate, requiring continued employment and performance.

Future Outlook

The future outlook is implicitly tied to the vesting schedule and the long-term nature of the stock options, indicating an expectation of continued employment and potential stock price appreciation over the next decade.

Industry Context

Granting stock options is a standard practice in the biotechnology and pharmaceutical industries to attract and retain key talent, especially in R&D-intensive roles like Chief Medical Officer, where long-term commitment is crucial for drug development cycles.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation across the biotech and pharma sectors.
• The size of the grant (242,000 options) and the vesting schedule (multi-year, cliff + monthly) are typical for a senior executive in a company of Immunome's size and stage, comparable to practices seen at emerging biotech firms listed on NASDAQ.

Related Party Transactions

• Grant of 242,000 employee stock options to Robert Lechleider, the Chief Medical Officer, which is a transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential for increased executive alignment with long-term stock performance.
• Employees: Standard executive compensation practice, potentially signaling stability in leadership.

Next Steps

• Continued vesting of the granted stock options, with 25% vesting on July 29, 2026.
• Monthly vesting of 1/36th of the remaining shares thereafter.
• Potential exercise of options by Robert Lechleider prior to the expiration date of July 28, 2035.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Immunome Inc. It reflects standard corporate governance and incentive alignment practices. Therefore, it does not warrant a change in an existing investment position.

Keywords

Immunome Inc., IMNM, Stock Options, Employee Stock Option, Robert Lechleider, Chief Medical Officer, Executive Compensation, Insider Transaction, Form 4, Biotechnology, Pharmaceuticals